PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
January 14, 2025 03:00 ET | Source: PulseSight Therapeutics S.A.S PARIS, Jan.…
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreichs Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting…
Research by City of Hope and Other Scientists May Help Patients Overcome Resistance to Chimeric Antigen Receptor (CAR) T Cell Therapy
Research on New System Published in Nature Biomedical Engineering Platform Engineers T…
Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024 19:08 ET | Source: Mesoblast Limited RYONCIL (remestemcel-L) is…
Nyxoah Announces Commercial Launch of Genio Innovative Therapy in England
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted…
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival…
Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Treatment effects sustained through long-term follow-up of beyond 10 years in the…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…
US FDA Grants Orphan Drug Designation to EXG110, a Novel Gene Therapy for Fabry Disease
Company also Provides Updates on wet Age Related Macular Degeneration and Rare…